Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12879099 | 1.00 | LTA4H (0.67) | LTA4HSIGMAR1DRD4ACHECYP2C19 | |
| SCHEMBL946495 | 1.00 | LTA4H (0.67) | LTA4HSIGMAR1DRD4ACHECYP2C19 | |
| SCHEMBL13308369 | 0.86 | LTA4H (0.57) | LTA4HSIGMAR1DRD4ACHECYP2C19 | |
| SCHEMBL10681787 | 0.86 | LTA4H (0.64) | LTA4HSIGMAR1DRD4ACHECYP2C19 | |
| SCHEMBL24803467 | 0.86 | LTA4H (0.57) | LTA4HSIGMAR1DRD4ACHECYP2C19 | |
| SCHEMBL31535374 | 0.85 | LTA4H (0.62) | LTA4HSIGMAR1DRD4ACHECYP2C19 | |
| SCHEMBL1875436 | 0.84 | LTA4H (0.65) | LTA4HSIGMAR1CYP2C19ALDH1A1MEN1 | |
| SCHEMBL2873528 | 0.84 | LTA4H (0.65) | LTA4HSIGMAR1CYP2C19ALDH1A1MEN1 | |
| SCHEMBL1875435 | 0.84 | LTA4H (0.65) | LTA4HSIGMAR1CYP2C19ALDH1A1MEN1 | |
| SCHEMBL334798 | 0.84 | LTA4H (0.60) | LTA4HSIGMAR1ACHECYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022269508-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2022-12-29 | — | — | WO | disclosed |
| EP-2139481-B1 | 1-[(2'-SUBSTITUTED)-PIPERAZIN-1'-YL]-ISOQUINOLINES AS NOREPINEPHRINE TRANSPORTER INHIBITOR THERAPEUTICS AND POSITRON EMISSION TOMOGRAPHY IMAGING AGENTS | UNIV MONTANA (US) | 2013-08-21 | — | — | EP | disclosed |
| US-7998962-B2 | Enantiomers of 2'-Fluoralky1-6-nitroquipazine as serotonin transporter positron emission tomography imaging agents and antidepressant therapeutics | THE UNIVERSITY OF MONTANA (US) | 2011-08-16 | — | — | US | disclosed |
| US-7887784-B2 | Potent and selective binding affinity for the norpeinephrine transporter (NET) protein found in peripheral and central nervous system tissues | UNIVERSITY OF MONTANA (US) | 2011-02-15 | — | — | US | disclosed |
| US-20110009419-A1 | Enantiomers of 2'-Fluoralkyl-6-nitroquipazine as Serotonin Transporter Positron Emission Tomography Imaging Agents and Antidepressant Therapeutics | GERDES JOHN M | 2011-01-13 | — | — | US | disclosed |
| US-7812162-B2 | Enantiomers of 2′-fluoralkyl-6-nitroquipazine as serotonin transporter positron emission tomography imaging agents and antidepressant therapeutics | THE UNIVERSITY OF MONTANA (US) | 2010-10-12 | — | — | US | disclosed |
| US-20080267870-A1 | 1-[(2'-Substituted)-piperazin-1' -yl]-isoquinolines as norepinephrine transporter inhibitor therapeutics and positron emission tomography imaging agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-10-30 | — | — | US | disclosed |
| US-20080058344-A1 | Enantiomers of 2'-fluoralkyl-6-nitroquipazine as serotonin transporter positron emission tomography imaging agents and antidepressant therapeutics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-03-06 | — | — | US | disclosed |
| US-4766125-A | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-08-23 | — | — | US | disclosed |
| EP-0068544-B1 | NOVEL N-ARYL-PIPERAZINEALKANAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-06-03 | — | — | EP | disclosed |
| EP-0068544-A2 | Novel N-aryl-piperazinealkanamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267870-A1 | 1-[(2'-Substituted)-piperazin-1' -yl]-isoquinolines as norepinephrine transporter inhibitor therapeutics and positron emission tomography imaging agents | SLC6A2, SLC6A4, SLC6A3 | LTA4H 3369/4885SIGMAR1 51/4885DRD4 37/4885 |
| US-20110009419-A1 | Enantiomers of 2'-Fluoralkyl-6-nitroquipazine as Serotonin Transporter Positron Emission Tomography Imaging Agents and Antidepressant Therapeutics | SLC6A4, SLC18A2, HTR6 | LTA4H 2848/4885SIGMAR1 62/4885DRD4 633/4885 |
| US-20080058344-A1 | Enantiomers of 2'-fluoralkyl-6-nitroquipazine as serotonin transporter positron emission tomography imaging agents and antidepressant therapeutics | SLC6A4, SLC18A2, HTR3A | LTA4H 3054/4885SIGMAR1 53/4885DRD4 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.